Close Menu
Home › Asuragen to Develop IVD Kits on Thermo Fisher Scientific's CE Platform

Asuragen to Develop IVD Kits on Thermo Fisher Scientific's CE Platform

Feb 21, 2017

NEW YORK (GenomeWeb) – Asuragen said today that it is collaborating with Thermo Fisher Scientific to develop and commercialize capillary electrophoresis-based in vitro diagnostics.

Asuragen, based in Austin, Texas, will develop diagnostic kits for Thermo Fisher’s 3500 Dx Series Genetic Analyzer CS2 instrument, using its AmplideX PCR/CE technology, which enables the analysis of repetitive DNA sequences, and its AmplideX Reporter analytics and reporting software. The products will be built under design control and manufactured at Asuragen's cGMP facility.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jun
18
Featured Webinar

Clinical Genomics of NTRK Fusion Detection in Cancer

Sponsored by
ArcherDX

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect. 

Jun
19
Featured Webinar

Genome-Wide NIPT for Rare Chromosomal Conditions: Technical, Biological, and Clinical Considerations

This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.

Jun
25
Featured Webinar

Error-Corrected Sequencing to Detect Measurable Residual Disease in Post-Transplant MDS Cases

Jul
23
Featured Webinar

A Novel Quality Improvement Model to Support Molecular Testing of Oncology Patients

Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

What's Popular?

In Molecular Diagnostics

  1. USPTO Denies Foundation Medicine Attempt to Invalidate Guardant Health Patent

  2. BGI Genomics Continues to Grow Clinical Testing Business, Add Partnerships

    Premium

  3. Bio-Techne Gets New York State Approval for Prostate Cancer Test

  4. ASCO Data Pushes Boundaries for Genomic Testing in Localized Breast Cancer

    Premium

  5. FDA Clears Roche Extraction Platform For Use With Applied BioCode GI Pathogen Panel, System

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.